Pazopanib’s selectivity towards thyroid cancer stems from its ability to inhibit key tyrosine kinase pathways, such as VEGFR, PDGFR, and c-Kit, which are crucial in thyroid cancer pathogenesis due to frequent mutations and overexpression in these pathways. Here, PDGFRB is linked to thyroid gland carcinoma.